Andrew D. Campbell

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future

Steven M. Mennen, Carolina Alhambra, C. Liana Allen et al. · Organic Process Research & Development · 2019 · 570 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +15

Protodeboronation of Heteroaromatic, Vinyl, and Cyclopropyl Boronic Acids: pH–Rate Profiles, Autocatalysis, and Disproportionation

Paul Alan Cox, Andrew G. Leach, Andrew D. Campbell et al. · Journal of the American Chemical Society · 2016 · 371 citations · Full text

Natural Sciences, Chemical Engineering, Chemical Kinetics +14

Base-Catalyzed Aryl-B(OH)₂ Protodeboronation Revisited: From Concerted Proton Transfer to Liberation of a Transient Aryl Anion

Paul Alan Cox, Marc Reid, Andrew G. Leach et al. · Journal of the American Chemical Society · 2017 · 312 citations · Full text

Natural Sciences, Chemistry, Catalysis +15

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,3-dihydro-2<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-2-one)

Kurt G. Pike, Bernard Barlaam, Elaine Cadogan et al. · Journal of Medicinal Chemistry · 2018 · 116 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14